Thursday, 12 October 2017

Tofacitinib for moderate to severe rheumatoid arthritis [TA480]

New Guidance from NICE:

Evidence-based recommendations on tofacitinib (Xeljanz) for treating moderate to severe rheumatoid arthritis in adults.

1 Recommendations

1.1 Tofacitinib, with methotrexate, is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with a combination of conventional disease-modifying anti-rheumatic drugs (DMARDs), only if:
  • disease is severe (a disease activity score [DAS28] of more than 5.1) and
  • the company provides tofacitinib with the discount agreed in the patient access scheme.